Buy Carprofen Online, rx medicine for dogs

Carprofen (Rx)

SKU: N/A Category:

Product Description

Novox 100 mg, 180 Caplets (Carprofen) is a non-steroidal, anti-inflammatory drug (NSAID) used to treat pain and inflammation in dog. By inhibiting the activity of cyclooxygenase, Novox pet meds reduces pain and inflammation in dogs associated with arthritic dog and hip dysplasia dogs.

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen.

This dog medication for pain is manufactured by Norbrook Laboratories Limited.

You can order the dog medication for pain other veterinary medicines for dogs at our online pet meds shop. At our Texas based pet pharmacy online, we offer quality veterinary medications.

For
This arthritis meds for dogs is for oral use in dogs only.

CAUTION:
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Benefits:

  • Non-steroidal, anti-inflammatory drug (NSAID) for dogs
  • Relives pain due to arthritis in dogs and hip dysplasia in dogs
  • Relives pain due to arthritis in dogs and hip dysplasia in dogs
  • Available as easy-to-administer caplets

CLINICAL PHARMACOLOGY:
Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models.

The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Several studies have demonstrated that carprofen has modulatory effects on both humoral and cellular immune responses.

INDICATIONS:
Carprofen is indicated for the relief of pain and inflammation in dogs associated with osteoarthritis and for the control of postoperative pain in dogs associated with soft tissue surgeries and orthopedic surgeries in dogs.

CONTRAINDICATIONS:
Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

PRECAUTIONS:
As a class, cyclooxygenase inhibitory non-steroidal anti-inflammatory drug may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid.

When NSAlDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients.

NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy.

The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAlDs perioperatively.

Carprofen is a non-steroidal anti-inflammatory drug, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or gastrointestinal perforations, concomitant use carprofen and other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of carprofen, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another non-steroidal anti-inflammatory drug is not recommended. Sensitivity to drug-associated adverse reactions varies with the individual patient. Carprofen treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in dogs.

Novox® Caplets, dog medication for pain is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand’s disease), as safety has not been established in dogs with these disorders. The safe use of Novox® Caplets in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established. Studies to determine the activity of carprofen when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted.

Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce the level of inhalant anesthetics needed.

If additional dog medication for pain is warranted after administration of the total daily dose of Novox® Caplets, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID therapy to another or when switching from corticosteroid use to NSAID use.

WARNINGS:

  • Keep out of reach of children. Not for human use.
  • Consult a physician in cases of accidental ingestion by humans.
  • For use in dogs only.
  • Do not use in cats.
  • All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy.
  • All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy.
  • Owners should be advised to observe for signs of potential drug toxicity.

INFORMATION FOR DOG OWNERS
Novox® Caplets, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance.

Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes.

Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes.

Owners should be advised to discontinue Novox® Caplets therapy and contact their veterinarian immediately if signs of intolerance are observed.

The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

ADVERSE REACTIONS:
During investigational studies of osteoarthritis in dogs with twice daily administration of 1 mg/lb, no clinically significant adverse reactions were reported. Some clinical signs were observed during field studies (n=297) which were similar for carprofen caplet- and placebo-treated dogs. Incidences of the following were observed in both groups: vomiting (4%), diarrhea (4%), changes in appetite (3%), lethargy (1.4%), behavioral changes (1%), and constipation (0.3%). The product vehicle served as control.

There were no serious adverse events reported during clinical field studies with once daily oral administration of 2 mg/lb of this canine pain relief medicine. The following categories of abnormal health observations were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Clinical Field Study (2 mg/lb once daily)

Observationcarprofen (n=129)Placebo (n=132)
Inappetence1.61.5
Vomiting3.13.8
Diarrhea/Soft stool3.14.5
Behavior change0.80.8
Dermatitis0.80.8
PU/PD0.8
SAP increase7.88.3
ALT increase5.44.5
AST increase2.32.3
BUN increase3.11.5
Bilirubinuria16.312.1
Ketonuria14.79.1

Clinical pathology parameters listed represent reports of increases from pre-treatment values; medical judgment is necessary to determine clinical relevance.

During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control.

During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control.

Observation*carprofen (n=148)carprofen (n=148)
Vomiting10.113.4
Diarrhea/Soft stool6.16.0
Ocular disease2.70
Inappetence1.40
Dermatitis/skin lesion2.01.3
Dysrhythmia0.70
Apnea1.40
Oral/periodontal disease1.40
Pyrexia0.71.3
1.31.31.3
Wound drainage1.40

* A single dog may have experienced more than one occurrence of an event.

Post-Approval Experience:
Although not all adverse reactions are reported after using this dog medication, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system.

Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.

Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.

Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.

Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.

Dermatologic: Pruritis, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecchymosis.

Immunologic or hypersensitivity: Facial swelling, hives, erythema .In rare situations, death has been associated with some of the adverse reactions listed above.

To report a suspected adverse reaction call 1-888-708-3326.

DOSAGE AND ADMINISTRATION:
Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Carprofen and other treatment options before deciding to use

Carprofen. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for oral administration of these caplets to dogs is 2 mg/lb (4.4 mg/kg) of body weight daily. The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb (2.2 mg/kg) twice daily. For the control of postoperative pain in dogs, administer approximately 2 hours before the procedure. Caplets are scored and dosage should be calculated in half-caplet increments.

EFFECTIVENESS:
Confirmation of the effectiveness of carprofen for the relief of pain and inflammation in dogs associated with osteoarthritis and for the control of postoperative pain in dogs associated with soft tissue and orthopedic surgery, was demonstrated in 5 placebo-controlled, masked studies examining the anti-inflammatory and analgesic effectiveness of carprofen in various breeds of dogs.

Separate placebo-controlled, masked, multicenter field studies confirmed the anti-inflammatory and analgesic effectiveness of carprofen when dosed at 2 mg/lb once daily or when divided and administered at 1 mg/lb twice daily. In these two field studies, dogs diagnosed with osteoarthritis showed statistically significant overall improvement based on lameness evaluations by the veterinarian and owner observations when administered carprofen at labeled doses.

Separate placebo-controlled, masked, multicenter field studies confirmed the effectiveness of carprofen for the control of postoperative pain in dogs when, dosed at 2 mg/lb once daily in various breeds of dogs. In these studies, dogs presented for ovariohysterectomy, cruciate repair and aural surgeries were administered carprofen preoperatively and for a maximum of 3 days (soft tissue) or 4 days (orthopedic) postoperatively. In general, dogs administered carprofen showed statistically significant improvement in pain scores compared to controls.

ANIMAL SAFETY STUDIES:
Laboratory studies in unanesthetized dogs and clinical field studies have demonstrated that carprofen pet medication is well tolerated in dogs after oral administration.

In target animal safety studies, carprofen was administered orally to healthy Beagle dogs at 1, 3, and 5 mg/lb twice daily (1, 3 and 5 times the recommended total daily dose) for 42 consecutive days with no significant adverse reactions. Serum albumin for a single female dog receiving 5 mg/lb twice daily decreased to 2.1 g/dL after 2 weeks of treatment, returned to the pre-treatment value (2.6 g/dL) after 4 weeks of treatment, and was 2.3 g/dL at the final 6-week evaluation. Over the 6-week treatment period, black or bloody stools were observed in 1 dog (1 incident) treated with 1 mg/lb twice daily and in 1 dog (2 incidents) treated with 3 mg/lb twice daily.

Redness of the colonic mucosa was observed in 1 male that received 3 mg/lb of this pet meds twice daily.

Two of 8 dogs receiving 10 mg/lb orally twice daily (10 times the recommended total daily dose) for 14 days exhibited hypoalbuminemia. The mean albumin level in the dogs receiving this dose was lower (2.38 g/dL) than each of 2 placebo control groups (2.88 and 2.93 g/dL, respectively). Three incidents of black or bloody stool were observed in 1 dog. Five of 8 dogs exhibited reddened areas of duodenal mucosa on gross pathologic examination. Histologic examination of these areas revealed no evidence of ulceration, but did show minimal congestion of the lamina propria in 2 of the 5 dogs.

In separate safety studies lasting 13 and 52 weeks, respectively, dogs were administered orally up to 11.4 mg/lb/day (5.7 times the recommended total daily dose of 2 mg/lb) of carprofen, canine pain relief medicine. In both studies, the drug was well tolerated clinically by all of the animals. No gross or histologic changes were seen in any of the treated animals. In both studies, dogs receiving the highest doses had average increases in serum L-alanine aminotransferase (ALT) of approximately 20 IU.

In the 52-week study, minor dermatologic changes occurred in dogs in each of the treatment groups but not in the control dogs. The changes were described as slight redness or rash and were diagnosed as non-specific dermatitis. The possibility exists that these mild lesions were treatment related, but no dose relationship was observed.

Clinical field studies were conducted with 549 dogs of different breeds at the recommended oral doses for 14 days (297 dogs were included in a study evaluating 1 mg/lb twice daily and 252 dogs were included in a separate study evaluating 2 mg/lb once daily). In both studies the pet meds was clinically well tolerated and the incidence of clinical adverse reactions for carprofen-treated animals was no higher than placebo-treated animals (placebo contained inactive ingredients found in carprofen caplets). For animals receiving 1 mg/lb twice daily, the mean post-treatment serum ALT values were 11 IU greater and 9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. In the latter study, 3 carprofen-treated dogs developed a 3-fold or greater increase in (ALT) and/or (AST) during the course of therapy. One placebo-treated dog had a greater than 2-fold increase in ALT. None of these animals showed clinical signs associated with the laboratory value changes. Changes in clinical laboratory values (hematology and clinical chemistry) were not considered clinically significant. The 1 mg/lb twice daily course of therapy was repeated as needed at 2-week intervals in 244 dogs, some for as long as 5 years.

Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic surgery or soft tissue surgery. Dogs were administered 2 mg/lb of carprofen caplets two hours prior to surgery then once daily, as needed for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). This canine pain relief medicine was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observations in carprofen- and placebo-treated animals were approximately equal and few in number (see Adverse Reactions). The most frequent abnormal health observation was vomiting and was observed at approximately the same frequency in carprofen- and placebo-treated animals. Changes in clinicopathologic indices of hematopoetic, renal, hepatic, and clotting function were not clinically significant. The mean post-treatment serum ALT values were 7.3 IU and 2.5 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. The mean post-treatment AST values were 3.1 IU less for dogs receiving carprofen and 0.2 IU greater for dogs receiving placebo.

STORAGE:
Store this dog medication for pain at controlled room temperature 15°-30°C (59° – 86°F).

HOW SUPPLIED:
Novox® Caplets are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per caplet. Each caplet size is packaged in bottles containing 30, 60, or 180 caplets.

NDC
25 mg30 CAPLETS50989-236-02001702L01
60 CAPLETS50989-236-50002762L01
180 CAPLETS50989-236-86024670L01
75 mg30 CAPLETS50989-238-0250989-238-02
60 CAPLETS50989-238-50005762L01
180 CAPLETS50989-238-86006762L01
100 mg30 CAPLETS50989-245-02007762L01
60 CAPLETS50989-245-50008762L01
180 CAPLETS50989-245-86009762L01

Manufactured By: Norbrook Laboratories Limited, Newry, Northern Ireland

Distributed By: Vedco, Inc., St. Joseph, MO 64507

Additional Information

Bottle Size

100mg Caplets, 180 ct, 100mg Caplets, 60 ct, 100mg Chewable, 60 ct, 25mg Caplets, 180 ct, 25mg Caplets, 60 ct, 25mg Chewable, 60 ct, 75mg Caplets, 180 ct, 75mg Caplets, 60 ct, 75mg Chewable, 60 ct

Product Type

Nutrition Medicine, OTC Medicine, Rx Medicine

Reviews

There are no reviews yet.

Be the first to review “Carprofen”

Your email address will not be published. Required fields are marked *